NewsBenzinga노보 노디스크, 일요일 발표···비만주간에서 카그리세마의 REDEFINE 1 사후 분석 결과 2건 공개: 초기 반응자에서 평균 체중 감소율 25.4%, 유의미한 신체 기능 개선율 73.1% 대 49.1% 노보 노디스크, 일요일 발표···비만주간에서 카그리세마의 REDEFINE 1 사후 분석 결과 2건 공개: 초기 반응자에서 평균 체중 감소율 25.4%, 유의미한 신체 기능 개선율 73.1% 대 49.1% Benzinga 2026.11.16 06:38 (GMT+0) Open on Benzinga Other news Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 What's Going on With AST SpaceMobile Stock on Monday? Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years Stock of the Day: Is Pepsi About to Break Out? Intel Extends Slide as Nvidia Trims Stake 25%, Shareholder Suit Adds Pressure HC Wainwright & Co. Maintains Buy on Soluna Holdings, Lowers Price Target to $3
Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years